The FDA Just Added a Vision Warning to GLP-1 Labels. Here's How to Read It.

A rare eye condition is now part of the official safety picture for one of the most widely used drug classes in medicine. The bigger story is what that says about medicine at scale.

On November 9, the FDA announced it is requiring makers of GLP-1 receptor agonist medications to add a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION, to the Warnings and Precautions section of their labels. The list of affected drugs includes household names like Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity, along with the newer oral pill Foundayo.

My read: this is not a verdict against GLP-1s. It's what happens when a drug class goes from breakthrough to mainstream. Once millions of people are taking related medications, rare signals that were hard to see in early clinical trials can start to surface. The real test is how well those signals get detected, measured and communicated. This update is a clear example of that process at work.

What NAION Actually Is

NAION is often described as an "eye stroke." Blood flow to the front of the optic nerve drops, and the FDA describes the result as sudden, painless vision loss in one eye that can be permanent. Patients frequently notice it on waking. It is also rare. According to the FDA, adults over 50 develop NAION at a background rate of roughly 2.3 to 10.2 cases per 100,000 people per year.

The known risk factors include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. Many of those are common among people who take GLP-1s, which is a big reason this question has been so difficult to untangle. The FDA's wording reflects that. The agency concluded there is a potential increased risk of rare NAION events. It did not conclude that the drugs cause NAION.

What the Evidence Showed

The question gained attention in July 2024, when a study in JAMA Ophthalmology suggested a possible link between semaglutide and NAION. The FDA noted limitations in that study but decided the issue warranted a closer look, and it pulled from several sources.

A meta-analysis of 126 randomized trials, covering more than 134,000 patients, found 15 probable NAION cases in total. That worked out to about 6.4 cases per 100,000 patient-years among people on GLP-1s, compared with 3.8 among those on comparison treatments. The FDA also ran a real-world study through its Sentinel system, looking at adults with type 2 diabetes starting treatment. GLP-1 users showed a higher rate than people starting DPP-4 inhibitors, another class of diabetes medication, while the difference compared with SGLT-2 inhibitors was not statistically significant. Animal studies did not identify a mechanism.

Two takeaways stand out. First, the absolute numbers are small. In the trial data, the gap is about 2.6 extra cases per 100,000 patient-years. European regulators, who recommended adding NAION to semaglutide labels in 2025, reached a similar conclusion, estimating roughly one additional case per 10,000 person-years of treatment in adults with type 2 diabetes and classifying it as "very rare."

Second, the signal varies depending on what GLP-1s are compared against. That pattern suggests a real but modest effect, one where a patient's underlying health likely matters a great deal.

The real test of any breakthrough at scale is how well its rare signals get detected, measured and communicated.

The Math of Scale

This is where the investor in me pays attention. A risk of roughly one in 10,000 per year is very small for any one person. Spread across millions of patients, it can add up to a meaningful number of people. Both things can be true at once, and the right response is precision, not panic.

The FDA's guidance is practical. Patients are advised to contact a health care professional right away if they notice sudden vision changes in one eye, such as blurred or missing areas of vision or changes in color. Clinicians are advised to refer suspected cases promptly to an ophthalmologist and to consider stopping the medication if NAION develops, unless the benefits clearly outweigh the risk. People who have already had NAION face a higher risk of it happening again, so that group deserves an especially careful conversation with their doctor.

The benefit side of the ledger matters too. Beyond diabetes and weight management, some GLP-1s are approved to reduce major cardiovascular events in certain patients, slow kidney disease progression in people with type 2 diabetes and chronic kidney disease, treat obstructive sleep apnea in adults with obesity, and treat MASH, a serious form of fatty liver disease. Ophthalmologists quoted in recent coverage have generally said the potential risk should be weighed against those benefits rather than treated as a reason to avoid the drugs outright.

Where the Opportunity Is

When a widely used therapy reveals a rare risk, it often creates demand for tools that help manage it. The American Optometric Association already recommends an eye exam for patients starting a GLP-1. AI-assisted retinal imaging is already used in some clinics to screen for diabetic eye disease, and it's easy to imagine tools like that eventually helping clinicians establish baselines and track eye health over time for patients on these medications.

That's the pattern I look for. A large category creates a second-order need, and the companies that solve it, whether through diagnostics, monitoring or smarter patient selection, can become important parts of the ecosystem. GLP-1s are likely to remain a major part of medicine. The tools around them are likely to get more sophisticated.

The Bottom Line

The FDA is not telling patients to stop taking GLP-1s. It's asking patients and doctors to be aware of a rare potential risk and to act quickly if symptoms appear. If you take one of these medications, it's worth knowing the warning signs, asking your doctor whether an eye exam makes sense for you, and discussing any concerns before making changes, especially if you have a history of NAION or several of its risk factors.

The most powerful medicines of this era will keep teaching us things early trials couldn't show. The people and companies that pay closest attention to that information will be best positioned for what comes next.

"Breakthroughs don't end with approval. They mature through real-world lessons, and the people who listen closest to the data build what comes next."

— Paul Gravette, CEO & Founder, Gravette Capital

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional diagnosis or treatment. Always consult a qualified health care provider before starting, stopping, or changing any medication. Information is based on the FDA Drug Safety Communication issued November 9, 2026, and other publicly available sources believed to be reliable as of publication; findings may change as research continues. References to publicly traded companies or their products are not investment recommendations. Forward-looking statements about markets and technologies reflect the author's opinions and are subject to uncertainty. Gravette Capital and its affiliates may hold positions in companies within the health and wellness sector.